# US 9,296,784 B2 · Mesothelin vaccines and model systems > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,296,784 B2 - Document ID: US9296784B2 - Status: Granted - Kind: B2 - Application number: 14/042,812 - Filed: 2013-10-01 - Published: 2014-02-20 - Granted: 2016-03-29 - Earliest claimed: 2002-07-12 - Assignees: The Johns Hopkins University - Applicants: The Johns Hopkins University - Inventors: Elizabeth Jaffee; Ralph Hruban - Web page: https://patentgrep.com/patent/US9296784B2 ## CPC - A61K 39/0208: {Specific bacteria not otherwise provided for} - A61K 39/001168: {Mesothelin [MSLN]} - A61P 35/00: Antineoplastic agents - A61P 37/04: Immunostimulants - C07K 7/06: having 5 to 11 amino acids - C07K 16/30: from tumour cells - C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora - C12N 15/8509: {for producing genetically modified animals, e.g. transgenic} - A01K 2267/0331: Animal model for proliferative diseases - A61K 2039/505: {comprising antibodies} - A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages} - A61K 2039/52: {Bacterial cells; Fungal cells; Protozoal cells} - A61K 2039/522: {avirulent or attenuated} - A61K 2039/523: {expressing foreign proteins} - A61K 2039/53: {DNA (RNA) vaccination} - A61K 2039/55511: {Organic adjuvants} - A61K 2039/55522: {Cytokines; Lymphokines; Interferons} - A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2} - A61K 2039/6031: {Proteins} - C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE} - C12N 2710/16522: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2740/13043: viral genome or elements thereof as genetic vector - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line. ## Claims ### Claim 1 A method of treating a patient with a cancer that overexpresses mesothelin relative to normal tissue from which the cancer is derived, said method comprising: administering to the patient a composition comprising a polypeptide consisting of 9 to 25 contiguous amino acid residues of mesothelin, said polypeptide comprising VLPLTVAEV (SEQ ID NO: 2), under conditions in which a T-cell response to mesothelin is induced, wherein the composition does not comprise whole tumor cells. ### Claim 2 (depends on 1) The method of claim 1 wherein the patient has undergone surgery to remove the cancer. ### Claim 3 (depends on 1) The method of claim 1 wherein the cancer that overexpresses mesothelin is pancreatic cancer. ### Claim 4 (depends on 3) The method of claim 3 wherein the patient has undergone surgery to remove the pancreatic cancer. ### Claim 5 (depends on 1) The method of claim 1 wherein mesothelin-specific CD8+ T cells are induced in the patient. ### Claim 6 (depends on 1) The method of claim 1 wherein the composition is acellular. ### Claim 7 (depends on 1) The method of claim 1 wherein the composition comprises Listeria monocytogenes bacteria, and the bacteria express the polypeptide. ### Claim 8 (depends on 1) The method of claim 1 wherein the composition is administered in sufficient amount to keep the patient tumor-free after removal of the tumor. ### Claim 9 (depends on 1) The method of claim 1 wherein the composition comprises dendritic cells. ### Claim 10 (depends on 1) The method of claim 1 wherein the tumor is selected from the group consisting of: ovarian cancer, pancreatic cancer, mesothelioma, and squamous cell carcinomas of the esophagus, lung, and cervix. ### Claim 11 (depends on 1) The method of claim 1 wherein the polypeptide is fused to another polypeptide or a carrier protein. ### Claim 12 (depends on 11) The method of claim 11 wherein the polypeptide is fused to a carrier protein and the carrier protein is selected from the group consisting of CD40 ligand, OX-40 ligand, CTLA-4 antagonist, and GM-CSF. ### Claim 13 (depends on 1) The method of claim 1 wherein the polypeptide is less than 15 amino acid residues. ### Claim 14 (depends on 1) The method of claim 1 wherein the polypeptide is less than 14 amino acid residues. ### Claim 15 (depends on 1) The method of claim 1 wherein the polypeptide is less than 13 amino acid residues. ### Claim 16 (depends on 1) The method of claim 1 wherein the polypeptide is less than 12 amino acid residues. ### Claim 17 (depends on 1) The method of claim 1 wherein the polypeptide is less than 11 amino acid residues. ### Claim 18 (depends on 1) The method of claim 1 further comprising the step of measuring induction of a T cell response. ### Claim 19 (depends on 1) The method of claim 1 further comprising the step of measuring induction of mesothelin-specific CD8+ T cells. ### Claim 20 (depends on 1) The method of claim 1 further comprising the step of measuring induction of a DTH response. ### Claim 21 (depends on 1) The method of claim 1 further comprising the step of administering a carrier for stimulating a CD8+ T cell or CD4+ T cell immune response, wherein the carrier is selected from the group consisting of: (a) a bacterial cell that is transformed to express the polypeptide, (b) an antigen presenting cell on whose surface the polypeptide is bound, and (c) a protein selected from the group consisting of CD40, CD40 ligand, OX-40, OX-40 ligand, CTLA-4 antagonist, and GM-CSF.